Semaglutide denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Semaglutide — and How to Navigate It

Prior authorization (PA) is BCBS's process for reviewing whether semaglutide is medically appropriate before agreeing to cover it. A denial at this stage is not a final answer — it is the start of a formal review process that you and your prescriber can engage with directly. Most PA denials for semaglutide are won on appeal when the clinical record is organized and complete.

## Why This Denial Happens

BCBS requires prior authorization for semaglutide because the drug carries significant cost and is prescribed across a range of indications and patient profiles. The plan reviews whether the request meets its internal coverage criteria — which draw from, but are not identical to, the FDA-approved prescribing information. Common reasons initial PA requests fail include incomplete documentation of prior treatments, missing diagnostic records, or a prescriber's letter that does not explicitly address each of BCBS's required criteria.

## Your Federal Appeal Rights

• Internal appeal of PA denial: File within 180 days of the denial notice. BCBS must issue standard appeal decisions within 30–60 days and urgent (expedited) decisions within 72 hours.
• External review (ACA §2719): After exhausting internal appeals, you have approximately 4 months from the final internal denial to request independent external review. The external reviewer is not bound by BCBS's internal criteria and applies clinical standards.
• Expedited review: If semaglutide is urgently needed for your health, request simultaneous expedited internal appeal and expedited external review — decisions can come within 72 hours.
• ERISA §503: Employer self-funded plans are subject to full-and-fair review under ERISA, with federal court as a backstop.

## Documentation to Gather

1. Diagnosis confirmation: Chart notes, lab results, and specialist records confirming the specific diagnosis for which semaglutide is being requested, with dates. 2. Prior-treatment history: A chronological list of every treatment tried before semaglutide — drug or non-drug — with start dates, stop dates, and documented outcomes. This is usually the most important piece of evidence. 3. Clinical severity documentation: Objective chart findings that establish the current severity of your condition and the clinical rationale for escalating to semaglutide. 4. Prescriber medical-necessity letter: Your prescriber should address every criterion in BCBS's PA policy explicitly, cite the FDA-approved prescribing information for semaglutide, and reference the applicable professional guideline organization (such as the ADA or relevant obesity-medicine society). 5. BCBS PA criteria: Request BCBS's prior-authorization criteria for semaglutide before submitting — this is your checklist.

## Criteria-Mapping Structure

Copy each PA criterion from BCBS's published policy and map it to a chart fact:

| BCBS PA Criterion | Supporting Chart Evidence | |---|---| | [Diagnosis/indication requirement] | [ICD-10 code, chart note, date confirmed] | | [Prior-treatment step requirement] | [Drug name, dates tried, documented outcome] | | [Clinical threshold or severity criterion] | [Objective chart finding, date, provider] |

Submit the completed table with the prescriber's letter and all records as a single organized packet. Reference each exhibit in the cover letter and clearly state the date of the denial you are appealing.